Susquehanna Fundamental Investments LLC Purchases New Holdings in Avid Bioservices, Inc. (NASDAQ:CDMO)

Susquehanna Fundamental Investments LLC acquired a new position in Avid Bioservices, Inc. (NASDAQ:CDMO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 68,492 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Susquehanna Fundamental Investments LLC owned 0.11% of Avid Bioservices as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in CDMO. FIL Ltd purchased a new stake in shares of Avid Bioservices in the 4th quarter worth approximately $31,598,000. Alpine Associates Management Inc. purchased a new stake in shares of Avid Bioservices in the fourth quarter worth $24,034,000. Water Island Capital LLC bought a new position in shares of Avid Bioservices during the fourth quarter valued at $19,715,000. Hsbc Holdings PLC purchased a new position in shares of Avid Bioservices in the 4th quarter worth about $18,865,000. Finally, Alliancebernstein L.P. boosted its stake in Avid Bioservices by 1,469.6% in the 4th quarter. Alliancebernstein L.P. now owns 1,186,003 shares of the biopharmaceutical company’s stock worth $14,647,000 after purchasing an additional 1,110,443 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

Avid Bioservices Stock Up 0.1 %

NASDAQ:CDMO opened at $12.50 on Friday. The company has a debt-to-equity ratio of 3.58, a quick ratio of 0.92 and a current ratio of 1.30. The firm has a market cap of $799.18 million, a P/E ratio of -5.23 and a beta of 1.39. Avid Bioservices, Inc. has a fifty-two week low of $6.53 and a fifty-two week high of $12.51. The firm has a 50-day simple moving average of $12.50 and a two-hundred day simple moving average of $12.17.

Avid Bioservices Profile

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.